Results 1 to 10 of about 2,511 (148)

Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis [PDF]

Life, 2023
Background: Recalcitrant neovascular age-related macular degeneration (rnAMD) despite intensive intravitreal anti-neovascular endothelial growth factor (VEGF) treatment, can be handled by switching to another anti-VEGF agent. This first systematic review
Christof Hänsli, Christin Schild, Isabel Pfister, Justus G. Garweg   +3 more
doaj   +3 more sources

Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy [PDF]

Pharmaceuticals
Purpose: The aim was to compare the short-term outcomes of aflibercept 8 mg and brolucizumab for the treatment of polypoidal choroidal vasculopathy (PCV). Methods: This study included 48 eyes of 48 patients with PCV.
Yoshiko Fukuda, Yoichi Sakurada, Yumi Kotoda, Misa Kimura, Kenji Kashiwagi   +4 more
doaj   +2 more sources

Effectiveness, Safety, and Real-World Experience of Brolucizumab: A Systematic Review [PDF]

Pharmaceuticals
Background/Objectives: Brolucizumab is a humanized single-chain antibody fragment with a molecular weight of approximately 26 kilodaltons (scFv, ~26 kDa) targeting all VEGF-A isoforms.
Naif M. Alali, Abeer Aljahdali, Hani B. AlBalawi, Othman Jarallah Al Jarallah, Salem Mohammed AL Zaid, Ismail Abuallut, Faisal ALMarek, Ibrahim Shajry, Yousef A. Alotaibi, Mohammad A. Hazzazi, Moustafa S. Magliyah   +10 more
doaj   +2 more sources

Side Effects of Brolucizumab [PDF]

Journal of Ophthalmic & Vision Research, 2021
Age-related macular degeneration and its complication, subretinal neovascularization, are common causes of progressive, irreversible impairment of central vision. Anti-vascular endothelial growth factor (anti-VEGF) therapy has improved the visual outcome
Tahmineh Motevasseli, Saeed Mohammadi, Fatemeh Abdi, William R. Freeman   +3 more
doaj   +5 more sources

Efficacy of Intravitreal Brolucizumab Switch in Pachychoroid Neovasculopathy [PDF]

Ophthalmology and Therapy
Introduction This study aimed to evaluate the anatomical and functional outcomes of switching to intravitreally administered brolucizumab (Beovu®, Novartis) in patients affected by pachychoroid neovasculopathy (PNV) who were considered as non-responders ...
Nicolò Ribarich, Marco Battista, Lisa Checchin, Riccardo Sacconi, Francesco Bandello, Giuseppe Querques   +5 more
doaj   +2 more sources

Comparison of one-year outcomes between aflibercept and brolucizumab for treatment-naïve pachychoroid neovasculopathy [PDF]

Scientific Reports
Pachychoroid neovasculopathy (PNV) is characterized by increased choroidal thickness, choroidal hyperpermeability, and fluid accumulation. Given its distinct pathophysiology, PNV requires management with anti-VEGF therapy, as its treatment response ...
Areum Jeong, Frenky Ramiro de Jesus, Seung Chul Baek, Min Sagong   +3 more
doaj   +2 more sources

Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration [PDF]

Ophthalmology and Therapy
Introduction To analyze visual and anatomical outcomes in patients switched to brolucizumab and previously treated with other intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents for exudative neovascular age-related macular ...
Federico Beretta, Ilaria Zucchiatti, Riccardo Sacconi, Federico Fantaguzzi, Stefano Lingardo, Francesco Bandello, Giuseppe Querques   +6 more
doaj   +2 more sources

Anti-vascular endothelial growth factor therapies in ophthalmology. [PDF]

Med Hypothesis Discov Innov Ophthalmol
Background: Retinal diseases, including neovascular age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, are leading causes of vision loss worldwide.
Koksaldi S, Karti O, Saatci AO.
europepmc   +3 more sources

Investigating the feasibility of selective anti-VEGF delivery to the retina using a microinvasive approach. [PDF]

Graefes Arch Clin Exp Ophthalmol
Background: Retinal therapeutics has been revolutionized by anti-vascular endothelial growth factor (VEGF) therapies, whereby intravitreal injection is the accepted delivery method.
Ching J, Arai M, Ooba M, Miyazato M, Kobayashi Y, Tanaka S, Kitahata S, Inoue T, Maruyama-Inoue M, Kadonosono K.   +9 more
europepmc   +3 more sources

Proactive Post-Injection Monitoring in Brolucizumab Therapy: A Study on Intraocular Inflammation and Treatment Outcomes [PDF]

Clinical Ophthalmology
Manoj Soman,1,2 Apoorva Jadhav,1,2 Abhaya Balakrishnan,1,2 Jay U Sheth,3 Unnikrishnan Nair1,2 1Department of Vitreoretinal Services, Chaithanya Eye Hospital and Research Institute, Trivandrum, India; 2Department of Research, Chaithanya Innovation in ...
Soman M, Jadhav A, Balakrishnan A, Sheth JU, Nair U   +4 more
doaj   +2 more sources